Tiedemann Advisors’s iBio IBIO Stock Holding History

Tiedemann Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-33	Closed	-$37K	–	324
2020 Q2	$37K	Buy	+33	New	+$21.6K	﹤0.01%	292

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Tiedemann Advisors's IBIO Position: Q3 2020 in Review

Tiedemann Advisors sold out of iBio (IBIO) in Q3 2020, closing a stake of 33 shares — an estimated $37K sold.

Tiedemann Advisors first reported a position in IBIO in Q2 2020 and held it in 1 quarter. The position peaked at $37K in Q2 2020. 77 funds tracked by Wall St. Rank hold IBIO as of Q3 2020.

Tiedemann Advisors reported no remaining iBio position as of Q3 2020 after selling out during the quarter.
Tiedemann Advisors sold 33 iBio shares in Q3 2020, an estimated $37K.
Tiedemann Advisors first reported a position in iBio in Q2 2020 and held it in 1 quarter.
Tiedemann Advisors's iBio position peaked at $37K in Q2 2020.
77 funds tracked by Wall St. Rank held iBio as of Q3 2020.

Based on Tiedemann Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.